AbbVie operates in a neutral market regime ( 18.7, 10Y 4.64%), but its defensive business model and low forward (15.77x) buffer rate headwinds. Fundamentals remain strong: 12.4% revenue growth, 72% gross margin, and a of 0.43 signal deep undervaluation. The stock closed at $256.91 on July 27, pulling back 1.3% from its July 24 high of $259.36, after a 6.4% one-month rally but still near the 52-week high of $262.10. Near-term technicals show improving momentum ( histogram narrowing, 63.4) but very low volume (0.87x 20-day avg) and a bearish divergence suggest cautious positioning ahead of the July 31 earnings. Consensus expects of $3.63 (+21% YoY), but estimates have softened slightly over the past 7 days (from $3.67). Analyst action remains supportive with multiple target raises (BMO $300, BofA $276, RBC $282). A recent negative catalyst: epcoritamab failed its Phase 3 overall survival endpoint, raising pipeline concerns. Key risks include oral competition to Skyrizi, the trial setback, and a potential earnings miss. The long-term thesis remains intact due to a deep pipeline, high margins, and attractive valuation. Overall, the stock is a core holding for defensive portfolios with long-term compounding potential, but near-term caution is warranted given low volume, divergence, trial overhang, and impending earnings uncertainty.
投资判断
实时价格
$256.91
推荐分数
73%
73%
置信度
78%
78%
各期限展望
1个月
持有
短线
6个月
买入
中期
1年
强力买入
长期
核心催化
The epcoritamab trial failure is a significant pipeline blow that could dampen enthusiasm for the oncology segment. The upcoming Q2 2026 earnings report on July 31 remains the highest-impact near-term catalyst, as it will test whether revenue and growth can meet lowered expectations.
Given the low-volume technical setup (0.87x avg volume), epcoritamab overhang, and proximity to earnings, consider 15-20% reduction for tactical traders ahead of the July 31 report. Long-term holders can maintain full position sizing. New positions should be initiated on dips to $250-255 for a better risk-reward entry.
投资逻辑快照
什么情况涨
The ratio of 0.43 remains deeply undervalued for a business with 72% gross margins, accelerating growth, and a pipeline of high-margin biologics. The post-Humira transition is succeeding, and recent analyst target raises confirm growing institutional confidence. Any pullback to support offers a re-entry point for long-term investors. The upcoming earnings could serve as a catalyst to break out above the 52-week high.
什么情况跌
If oral competitors (e.g., J&J's Icotyde) erode Skyrizi market share faster than expected, immunology growth could stall, triggering multiple compression. The epcoritamab trial failure raises doubts about oncology pipeline upside. Additionally, the $72.9B debt load could become a burden if cash flows disappoint. The low volume rally and bearish divergence suggest the market is not aggressively accumulating ahead of earnings, leaving room for a negative surprise. A miss on July 31, especially on given the negative ESP, could reverse the entire move from June lows.
A sustained close below $235 (50-day ) accompanied by a downward revision to full-year guidance at the Q2 earnings release would invalidate the bullish thesis.
Competitive erosion of Skyrizi by novel oral biologics from J&J (Icotyde) and others.
Epcoritamab trial failure limits oncology pipeline upside and may reduce long-term revenue expectations.
Regulatory pricing pressures under the Inflation Reduction Act (IRA) impacting future margins.
High debt load ($72.9B) if cash flow growth disappoints or interest rates remain elevated.
Event risk: a sizeable earnings miss could lead to a 5-10% correction.
接下来关注
下一次财报：2026年7月31日
The epcoritamab trial failure is a significant pipeline blow that could dampen enthusiasm for the oncology segment. The upcoming Q2 2026 earnings report on July 31 remains the highest-impact near-term catalyst, as it will test whether revenue and growth can meet lowered expectations.
信号仪表盘
决策输入
6 个信号
基本面
4.2%
距分析师均值目标空间
ABBV trades at a significant discount to growth and quality. of 15.77x is well below the sector average (~18-20x) and its historical mean. The ratio of 0.43 is deeply attractive, implying the market is not pricing in the expected earnings acceleration (FY26 consensus $14.13, +23% YoY estimated, FY27 $16.29). of 17.44x is reasonable for a business with 47.6% margins. FCF yield of 4.58% provides a strong margin of safety. The stock appears undervalued relative to its growth profile and peer set.
技术面
Neutral
趋势质量
Primary trend remains strongly bullish: price ($256.91) is well above the 50-day ($237.16) and 200-day ($222.25), and the / golden cross is intact. Price is trading just below the 52-week high ($262.10) after a rally from the June low ($217.60). The structure suggests a mature uptrend, with the stock consolidating near highs. A minor pullback to the 20-day ($252.02) would be constructive.
财报
3天
Accelerating
Q1 2026 adjusted of $2.65 missed consensus by $0.02 (-0.77%), but revenue exceeded by 1.5% and management raised full-year guidance to $14.08-$14.28, indicating strong underlying momentum.
新闻
Mixed-Bearish
新闻基调
The epcoritamab trial failure is a significant pipeline blow that could dampen enthusiasm for the oncology segment. The upcoming Q2 2026 earnings report on July 31 remains the highest-impact near-term catalyst, as it will test whether revenue and growth can meet lowered expectations.
宏观
Neutral
4.64% 10Y / 18.7 VIX
at 18.7 indicates neutral risk appetite. Rising 10Y yields above 4.6% can compress high- growth stocks, but ABBV's low forward and defensive business model make it relatively resilient. The defensive sector may benefit from flight-to-safety rotations amid growth stock volatility.
稳定性
Defensive Compounder
Core Anchor
AbbVie combines elite margins (72% gross, 32% operating), a robust pipeline (Skyrizi, Rinvoq, neuroscience), and a low beta (0.28) to deliver steady compounding. Strong FCF yield (~4.58%) and consistent dividend growth (2.7%) support a core anchor role. The balance sheet, while carrying net debt ($63.5B), is well-covered by operating cash flow ($21.2B). Drawdown risk stays low given defensive characteristics and institutional support (76.9% ownership). Near-term earnings event and recent trial setback add moderate risk but do not alter the long-term defensive profile.
分析师目标区间
均值目标
$267.79
高低目标
$200 / $328
分析师中值目标
$275.50
共识区间
$200 - $328
— 位分析师
Mean
$200$268$328
市场共识
Mean target of $267.79 implies ~4.2% upside from $256.91, with a wide range ($200-$328) reflecting uncertainty around pipeline and competitive dynamics. The skew is bullish: 24 of 31 analysts are Buy/Strong Buy. Recent target raises across multiple firms show strong institutional conviction despite near-term estimate drift. The high target of $328 suggests significant optionality in the pipeline.
筹码脉冲
内部人信号
Neutral
净偏向
No recent activity
内部人持股
0.1%
机构持股
76.9%
解读
Insider activity is minimal and provides no clear directional signal. The absence of selling during the recent rally is mildly positive but not decisive.
重要活动
Only transaction in period: CEO Richard Gonzalez exercised 6,000 shares 70 days ago with no value disclosed. No open-market purchases or sales. Insiders hold only 0.11% of shares, limiting signaling value.
市场背景
行业
Drug Manufacturers - General
Mixed-Bullish
情绪
34
跟踪股票
5
分组
industry
Drug Manufacturers - General 行业 当前情绪为 Mixed-Bullish，板块平均评分约 64 分，资金与评分正在同步走强，且leadership is concentrated in LLY, JNJ, NVO。
轮动线索
Drug Manufacturers - General 行业 组内平均推荐分数正在上修，说明资金偏好有扩散迹象。
Capital continues to rotate into companies with proven ADC platforms, but ABBV's recent epcoritamab trial failure adds caution. The company's ADC portfolio (Decnupaz, Elahere) still holds promise, but near-term pipeline sentiment has weakened. The theme is still important long-term but faces headwinds from this setback.
The epcoritamab failure has cast doubt on ABBV's broader oncology pipeline, even as other ADC assets advance.
Search for disruptive innovation in targeted cancer therapies.
Institutional accumulation of diversified oncology platforms with multiple late-stage assets.
Neuroscience & Aesthetics Growth
评分: 65
Mixed-Bullish
Neuroscience and aesthetics remain key growth engines for ABBV. The EU approval of Boey in July broadens the aesthetics portfolio. However, near-term news flow has been quieter, and the neuroscience pipeline is early-stage. The theme provides diversification and long-duration growth, but near-term momentum is moderate.
The European Commission's approval of Boey in July marks a major commercial milestone in aesthetics, broadening the portfolio beyond Botox-like products.
Capital rotation into high-margin neuroscience portfolios with long patent runways.
Growing market adoption of novel mechanisms in migraine and aesthetics with longer efficacy windows.
关键指标
23 项指标
市值
$453.91B
市盈率 (TTM)
125.3
远期市盈率
15.8
营收增速
12.4%
净资产收益率
0.0%
Beta 系数
0.28
完整指标集
另外 17 项指标
估值结构
估值倍数与现金流框架。
市销率
7.2
市净率
-68.2
企业价值 / EBITDA
17.4
质量与资产负债表
利润率、杠杆与流动性。
毛利率
72.0%
营业利润率
32.2%
资产负债率
0.0
流动比率
0.80x
速动比率
0.52x
仓位与价格区间
空头仓位与52周区间位置。
流通盘空头占比
1.4%
空头回补天数
2.42x
52周最高
$262.10
52周最低
$187.62
距52周高点
-2.0%
距52周低点
36.9%
公司分类
板块与行业背景。
板块
Healthcare
行业
Drug Manufacturers - General
其他信号
自由现金流
$20811624448.00
详细分析
估值
ABBV trades at a significant discount to growth and quality. of 15.77x is well below the sector average (~18-20x) and its historical mean. The ratio of 0.43 is deeply attractive, implying the market is not pricing in the expected earnings acceleration (FY26 consensus $14.13, +23% YoY estimated, FY27 $16.29). of 17.44x is reasonable for a business with 47.6% margins. FCF yield of 4.58% provides a strong margin of safety. The stock appears undervalued relative to its growth profile and peer set.
资产负债表
The balance sheet is solid but leveraged: $9.4B cash vs $72.9B total debt, net debt $63.5B (14% of market cap). However, operating cash flow of $21.2B covers interest and debt service comfortably (OCF/debt 0.29). Current ratio of 0.80 and quick ratio of 0.52 are low, but consistent cash generation mitigates liquidity risk. Debt is manageable given earnings power, though leverage warrants monitoring if cash flows slow.
增长
Revenue growth of 12.4% YoY is driven by Skyrizi (+29%) and Rinvoq (+20%), offsetting Humira erosion. Neuroscience and oncology diversify revenue. Earnings growth is expected to accelerate: FY26 consensus $14.13 (vs. $12.06 estimated for FY25? Not directly given, but forward growth appears strong). Margins are expanding as high-margin newer drugs scale, with operating margin at 32.16% and margin at 47.62%.
生意质量
Elite business quality with gross margin 72.03%, operating margin 32.16%, and margin 47.62%. Return on assets of 10.03% reflects efficient capital use despite heavy intangible assets. High barriers to entry from biologic manufacturing and patent protection support pricing power. Strong cash conversion enables reinvestment and dividends. The low beta (0.28) and institutional ownership (76.9%) confirm stable, recognized quality.
资本配置
Management balances R&D investment (ADC, neuro portfolio) with shareholder returns. Dividend yield of 2.7% is well-covered by FCF ($20.8B). The Apogee acquisition ($10.9B) enhances drug delivery. Capital deployment supports long-term compounding without impairing financial flexibility, though net debt remains elevated.
预期修正
Near-term estimates have softened over the past 30 days: 0q from $3.77 to $3.63, 0y from $14.25 to $14.13. However, +1y estimates remain stable at $16.29. Analyst actions show predominantly target raises (BMO to $300, BofA to $276, RBC to $282) in the last two weeks, signaling growing long-term conviction despite near-term drift. Overall, the revision signal is mixed but longer-term optimistic.